SAMSUNG-SEMICONDUCTOR
18.11.2020 10:02:08 CET | Business Wire | Press release
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics. Co., Ltd. has announced today that the relocation of its EMEA headquarters from the Frankfurt region to Munich, a leading high-tech hub in Germany, is now completed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005044/en/
Aiming to be on the doorstep of many key customers and partners with whom the company is driving digital transformation across industries, Samsung Semiconductor Europe started moving into the new Bavaria Towers in early 2020. Consolidating the already existing Ismaning office along the way, the relocation process was finally completed by closing the previous location near Frankfurt by end of September.
“Faster response times to our customers and attracting the best talent in this technology hub are key for Samsung Semiconductor Europe to remain a leading solution provider for the next few decades,” said Dermot Ryan, managing director at Samsung Semiconductor Europe. “By embracing future trends like artificial intelligence (AI), 5G, internet of things (IoT), big data, cloud computing, automotive and more, we work at the chip and basic software level, not only to make our own devices more intelligent, but also to enable entire industries to become smarter. The move to Munich marks a new era for Samsung Semiconductor Europe as we embark upon a new age of innovation, cooperation and trust together with our employees, customers and partners.”
“As the state capital of Bavaria, Munich is not only an international and culturally diverse city in a beautiful environment, it is also Germany‘s foremost tech hub and one of the leading cities in digital transformation,“ says Clemens Baumgärtner, head of the Department of Labor and Economic Development, City of Munich. “Munich offers excellent infrastructure and a vibrant ecosystem of companies, universities, start-ups and professional networks to companies in the areas of high-tech, IoT and services. We are more than happy to welcome Samsung Semiconductor Europe to shape the future of our region together.”
Munich has not only a leading position within Germany’s ICT sector, with 119.000 employees and 11.300 companies in and around the area according to the Bavarian Statistical Office , it also ranks high within European ICT poles of excellence, according to a study of the European Commission .
At Bavaria Towers, Samsung Semiconductor Europe employs around 170 staff from a large variety of countries in sales and marketing for Samsung Electronics’ component business units in Europe, the Middle East and Africa along with its sales offices in Finland, France, Turkey and the UK. From a technology point of view, Samsung Semiconductor Europe provides component solutions featuring industry-leading technologies in the areas of memory, system LSI, foundry, LED and display, often setting a new standard in the industry.
The company also offers a dynamic work culture in an exciting and inspiring atmosphere. As employees’ health and safety are one of its top priorities, the company provides a variety of employee benefits for improved work-life balance and thrives on a diverse and empowering work environment.
To learn more about Samsung Semiconductor Europe, please visit https://www.linkedin.com/showcase/samsung-semi-europe/
###
About Samsung Semiconductor Europe GmbH
Samsung Semiconductor Europe, a wholly owned subsidiary of Samsung Electronics Co. Ltd., is headquartered in Munich, Germany and operates offices in Europe, Middle East and Africa (EMEA). Samsung Semiconductor's European base handles the marketing and sales of Samsung Electronics' component business units including Memory, System LSI, Foundry, LED and Display in EMEA for various applications including servers, data centres, mobile, industrial/automotive, IoT and more. For more information, please visit www.samsung.com/semiconductor .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom